Transcept Pharmaceuticals plans to price public offering of its shares

Underwriters Leerink Swann and Lazard Capital Markets assist with sale

By Devika Patel

Knoxville, Tenn., April 25 - Transcept Pharmaceuticals, Inc. will price a public offering of common stock with a 30-day 15% greenshoe option, according to a preliminary prospectus supplement filed Wednesday with the Securities and Exchange Commission.

Leerink Swann LLC and Lazard Capital Markets LLC are the underwriters.

Proceeds will be used for general corporate purposes.

Transcept is a Point Richmond, Calif.-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.